Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14812210 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL2791362 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL14810578 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL14812149 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL16784599 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL29434443 | 1.00 | SLC6A3 (0.51) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL30592016 | 0.86 | F2RL1 (0.49) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL14503577 | 0.86 | SLC6A3 (0.53) | SLC6A3F2RL1MEN1HTTKMT2A | |
| SCHEMBL4368356 | 0.85 | SLC6A3 (0.61) | SLC6A3MEN1HTTKMT2APOLB | |
| SCHEMBL22831436 | 0.85 | SLC6A3 (0.61) | SLC6A3MEN1HTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758371-B1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2016-06-15 | — | — | EP | claimed |
| US-8927533-B2 | Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-06 | — | — | US | claimed |
| EP-2758371-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2014-07-30 | — | — | EP | claimed |
| WO-2013041480-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-03-28 | — | — | WO | claimed |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3305763-B1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | KYORIN SEIYAKU KK (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3075726-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kyorin Pharmaceutical Co., Ltd. (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2758371-B1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015087291-A1 | 3-CARBOXY-4-(R)-PHENYLPYRROLYDINE-2-ONE SALT AND ITS USE | JSC OLAINFARM (LV) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015079692-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | 杏林製薬株式会社 | 2015-06-04 | — | — | WO | disclosed |
| US-8927533-B2 | Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-06 | — | — | US | disclosed |
| EP-2758371-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041480-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | SLC6A3 2284/4885F2RL1 115/4885MEN1 2775/4885 |
| US-10464891-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | SLC6A3 2284/4885F2RL1 115/4885MEN1 2775/4885 |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | SLC6A3 2284/4885F2RL1 115/4885MEN1 2775/4885 |
| US-20170066718-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, FPR3 | SLC6A3 2284/4885F2RL1 115/4885MEN1 2775/4885 |
| US-11261155-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | SLC6A3 2284/4885F2RL1 115/4885MEN1 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.